Similarly, inhibition of T cell migration to GVHD target organs by targeting the chemokine receptors CCR2 or CCR5 protects against GVHD-induced pathology (44, 45), which at least with CCR2 deficiency was shown to preserve the GVL effect. Here, CCR5 is linked to graft versus host disease.